PARTICULARS TO APPEAR ON THE OUTER PACKAGE
CARTON BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Incurin 1 mg tablet

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:
Active substance: estriol 1 mg.

3. PACKAGE SIZE

30 tablets

4. TARGET SPECIES

Dog (bitch).

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 30 °C.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 01708/5038

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BLISTER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Incurin

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Estriol 1 mg/tablet

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Incurin 1 mg tablet

2. Composition

Each tablet contains:
Active substance:
Estriol 1 mg

White, round, single-scored tablets.

3. Target species

Dog (bitch).

4. Indications for use

For the treatment of hormone-dependent urinary incontinence due to sphincter mechanism incompetence in ovariohysterectomised (sterilised) female dogs.

5. Contraindications

Do not use in intact female dogs as the efficacy has only been established in ovariohysterectomised female dogs.
Do not use in animals with symptoms of polyuria-polydipsia.
Do not use in animals younger than 1 year.

6. Special warnings

Special warnings:
High doses of oestrogen may have a tumour-promoting effect in target organs with oestrogen receptors (mammary glands).

Special precautions for safe use in the target species:
In case of oestrogenic effects, the dose should be lowered.

Pregnancy and lactation:
The use is not recommended during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:
None known.

Overdose:
In case of overdose, typical oestrogen effects may occur. These effects are reversible after lowering the dose.

7. Adverse events

Dog (bitch):

Very common (> 1 animal / 10 animals treated):	Swollen vulva[1,2], mammary gland oedema[1,2], attractiveness to males[1,2]. Vomiting[1,2].
Rare (1 to 10 animals / 10 000 animals treated):	Vaginal haemorrhage. Alopecia.

[1] Observed at the highest recommended dose of 2 mg per dog.
[2] These effects are reversible after lowering the dose.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
E-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

A relationship between the final effective dose and body weight has not been established and therefore the dose must be determined for each dog on an individual basis.

Recommended dosing schedule:
Start treatment with 1 tablet (1 mg estriol) every day.
If treatment is successful, lower the dose to half a tablet per day.
If treatment is not successful, increase the dose to 2 tablets per day to be administered as a single dose.
Do not use more than 2 tablets per dog per day.
The minimum dose should not be less than half a tablet (0.5 mg estriol) per dog per day.
Ensure the dose used to achieve the therapeutic effect is as low as possible.

Some dogs do not need daily treatment. Once an effective daily dose has been established, treatment every other day may be tried.

If no response to treatment is achieved, the diagnosis should be reconsidered and other causes for the incontinence such as neurological disorders, bladder neoplasia, etc. investigated.

Animals should be re-examined every 6 months during treatment.

9. Advice on correct administration

See section 8.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 30 °C.

Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Vm 01708/5038

Pack size: carton box with 1 blister of 30 tablets.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:
MSD Animal Health UK Limited
Walton Manor
Walton
Milton Keynes
MK7 7AJ
United Kingdom
Tel.: +44 (0)1908 685685

Manufacturer responsible for batch release:
Intervet International B. V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

17. Other information

Estriol is a short-acting natural oestrogen. In the ovariohysterectomised female dog, it has a beneficial effect on urinary incontinence. After oral administration, a steady state is reached after the second treatment day, and no accumulation occurs after multiple doses. Because of its short acting action, estriol does not induce bone marrow suppression in the dog.

POM-V

Approved 29 December 2025

Gavin Hall